Clinical Trial Update: Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the comparability of ipratropium bromide HFA-134a inhalation aerosol to the Atrovent CFC inhalation aerosol in patients with chronic o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Atrovent CFC inhalation aerosol (ipratropium bromide)
• ipratropium bromide HFA-134a inhalation aerosol (ipratropium bromide)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED